We use cookies for a better user experience. Read our Privacy Policy

I Agree

Metformin Hydrochloride API Market Insights, 2021 - 2031

Metformin Hydrochloride API Market (Product: Metformin Hydrochloride, Metformin Hydrochloride DC, and Others; End User: Pharmaceutical Companies, Contract Research Organizations, and Others; and Dosage Form: Tablet, Extended Release Tablet, and Oral Solution) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Indian Companies Reduce Reliance on China for API Supply amid COVID-19 Pandemic

Due to the growing anti-China sentiment in India, manufacturers in the metformin hydrochloride API market are boosting their production capabilities to decrease reliance on China. Disruptions to supplies from China due to the COVID-19 pandemic have been a major factor for manufacturers to bolster local production of active pharmaceutical ingredients (APIs).

Though India is known as the pharmacy of the world for its massive production capabilities in generic drugs and vaccines, China is emerging as a stiff competition to India by accounting for half of the world API supply. Indian drug companies are turning to local producers in the metformin hydrochloride API market to end their reliance on China, as ties between the two countries sourced after a deadly border clash in June 2020. Executives at India’s Cipla, Biocon, Cadila Healthcare, and Sun Pharmaceutical are keen on reducing the dependence on richer rivals of raw materials.

To know the scope of our report Get a Sample on Metformin Hydrochloride API Market

Blending APIs with Glidant Candidates Help Overcome Challenges of Poor Powder Flow

Metformin hydrochloride (metformin HCl) is widely used as the first choice of medication for type 2 diabetes. However, processing of this API can be challenging and most dosage forms available on the market are prepared by wet granulation. In order to overcome the challenges of poor powder flow, lump formation glidants are being used and the ratio between pre- and main compression is being optimized to obtain tablets possessing suitable quality attributes. Manufacturers in the metformin hydrochloride API market are ensuring the unit operations of blending the API with the glidant candidates and tableting on a rotary press are being carried out by continuous processing.

Continuous manufacturing is drawing the attention of stakeholders in the pharmaceutical industry, owing to its advantages of reduction in scale-up challenges and real-time quality control.

Get a glimpse of the in-depth analysis through our Report Brochure

High Prevalence of Diabetes Mellitus Fueling Demand for Metformin HCl Tablets

Lupin Pharmaceuticals Inc. - an innovation-led pharmaceutical company in the U.S. has announced the launch of its Metformin HCl ER Tablets, 500 mg, and 1000 mg to the market, which are a generic equivalent of Santarus Inc.’s Glumetza® HCl ER Tablets, 500 mg, and 1000 mg. Manufacturers in the metformin hydrochloride API market are introducing tablets that are an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus.

Since high prevalence of diabetes mellitus in patients is characterized by a persistently elevated blood glucose associated with absent or inadequate pancreatic insulin secretion, manufacturers in the metformin hydrochloride API market are increasing their production capacities for tablets.

Metformin HCl Tablets Inhibit Process of Liver to Convert Glycogen into Sugar

The metformin hydrochloride API market is estimated to reach US$ 500 Mn by 2031. There is a growing demand for drugs that can control blood sugar levels for patients suffering from type 2 diabetes. Metformin HCl tablets help to reduce the amount of sugar produced by the liver, limit the amount of sugar absorbed into the body from the diet, and make insulin receptors more sensitive, which helps the body respond better to its own insulin.

Manufacturers in the metformin hydrochloride API market are increasing the availability of liquid and tablet forms of metformin HCl. Metformin HCl tablets are being publicized as oral anti-hyperglycemic medicines that are of paramount importance in the control and treatment of type 2 diabetes. The raw material powder of metformin hydrochloride API inhibits the process of the liver to convert glycogen into sugar. Manufacturers are increasing awareness about possible side effects such as digestive problem and nausea to improve patient quality of life.

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Indian drug companies are eyeing reliable local vendors who can promise consistency and competitive prices, due to the growing anti-China sentiment and reduced reliance on richer rival of raw materials during the COVID-19 pandemic. The metformin hydrochloride API market is witnessing the launch of new tablets that are equivalent to Santarus Inc.’s Glumetza® HCl ER Tablets, 500 mg, and 1000 mg. However, the processing of this API is potentially challenging, and most dosage forms available on the market are prepared by wet granulation. Hence, manufacturers should adopt continuous manufacturing and use of glidant candidates to process powdered form of metformin hydrochloride APIs.

Metformin Hydrochloride API Market: Overview

  • This report analyzes the current scenario and future prospects of the global metformin hydrochloride API market. Rise in prevalence of diabetes, surge in awareness about diabetes, and increase in geriatric population are the key factors projected to drive the global metformin hydrochloride API market during the forecast period.
  • The report includes an elaborate executive summary, which provides a snapshot of various segments of the global metformin hydrochloride API market. It also provides information and data analysis of the metformin hydrochloride API market about segments based on product, end user, dosage form, and region.
  • The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that impact the global metformin hydrochloride API market
  • The report includes company profiles, which provide information about their business, product portfolios, and competitive landscape in the global metformin hydrochloride API market
  • The report on the metformin hydrochloride API market offers market attractiveness analysis of regions and segments
  • The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global metformin hydrochloride API market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global metformin hydrochloride API market.

Metformin Hydrochloride API Market: Key Segments

  • In terms of product, the global metformin hydrochloride API market has been classified into metformin hydrochloride, metformin hydrochloride DC, and others. The metformin hydrochloride segment dominated the global market in 2020, owing to the availability of a range of products and presence of a large number of suppliers in the industry.
  • Based on end user, the global metformin hydrochloride API market has been categorized into pharmaceutical companies, contract research organizations, and others. The pharmaceutical companies segment dominated the global market in 2020, owing to increase in production of metformin hydrochloride drugs, rise in R&D, and presence of a large number of pharmaceutical companies.
  • In terms of dosage form, the global metformin hydrochloride API market has been divided into tablet, extended release tablet, and oral solution. The oral solution segment is expected to expand at a high CAGR from 2021 to 2031.
  • Market size and forecast for each of these segments have been provided from 2017 to 2031. The CAGR of respective segment has been provided from 2021 to 2031, considering 2020 as the base year.

Metformin Hydrochloride API Market: Regional Outlook

  • In terms of region, the global metformin hydrochloride API market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region considered in the market has been divided into countries/sub-regions.
  • The metformin hydrochloride API market report provides size and forecast for each region and country/sub-region from 2017 to 2031. The CAGR for each of these regions and countries has also been provided for the forecast period from 2021 to 2031. The metformin hydrochloride API market study also covers the competitive scenario in these regions.

Companies Covered in Metformin Hydrochloride API Market Report

  • Key players in the global metformin hydrochloride API market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the metformin hydrochloride API market report are
    • Auro Laboratories Limited
    • Abhilasha Pharma Pvt. Ltd.
    • Stanex Drugs & Chemicals Pvt. Ltd.
    • Fengchen Group Co., Ltd.
    • NS Chemicals
    • Midas Pharma GmbH
    • Harman Finochem Ltd.
    • Aarti Drugs Ltd.
    • Bayer AG
    • Ipca Laboratories Ltd.
    • Panacea Biotech Ltd.
    • Aristopharma Ltd.
    • Sihuan Pharmaceutical Holdings Group Ltd.
    • Intas Pharmaceuticals Ltd.
    • Bal Pharma Limited
    • Sohan Healthcare Pvt. Ltd.
    • JD Chem (I)
    • Kothari Phytochemicals & Industries Ltd.
    • Turtle Pharma Private Limited
    • Shijiazhuang Polee Pharmaceutical Co., Ltd.
    • Shouguang Fukang Pharmaceutical Co., Ltd.
    • USV Private Limited
    • Exemed Pharmaceuticals
    • Farmhispania Group
    • Shandong Keyuan Pharmaceutical Co., Ltd.
    • Merck KGaA
    • Taj API
    • Vistin Pharma AS
    • Wanbury Limited

Metformin Hydrochloride API Market – Segmentation

Product
  • Metformin Hydrochloride
  • Metformin Hydrochloride DC
  • Others
End User
  • Pharmaceutical Companies
  • Contract Research Organizations
  • Others
Dosage Form
  • Tablet
  • Extended Release Tablet
  • Oral Solution
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of metformin hydrochloride API market?

Metformin hydrochloride API market is estimated to reach US$ 500 Mn by 2031

What is the anticipated CAGR of the metformin hydrochloride API market in the forecast period?

Metformin hydrochloride API market is projected to expand at a CAGR of ~5% from 2021 to 2031

What are the key driving factors for the growth of the metformin hydrochloride API market?

Metformin hydrochloride API market is driven by rise in prevalence of diabetes, surge in awareness about diabetes

Which is the rising prominent segment in the metformin hydrochloride API market?

The metformin hydrochloride segment dominated the global metformin hydrochloride API market, and the trend is anticipated to continue during the forecast period.

Who are the key players in the global metformin hydrochloride API market?

Key players operating in the global metformin hydrochloride API market are Auro Laboratories Limited, Abhilasha Pharma Pvt. Ltd., Stanex Drugs & Chemicals Pvt. Ltd., Fengchen Group Co., Ltd., NS Chemicals

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Metformin Hydrochloride API Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Metformin Hydrochloride API Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Top 3 Players Operating in the Market Space

    5.2. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)

    5.3. Top Companies by Production Capacity, Production Volume, and Production Amount

    5.4. Top Countries by Production Capacity, Production Volume, and Production Amount

    5.5. Top Countries by Consumption Volume and Consumption Amount

    5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Metformin Hydrochloride API Market Analysis and Forecast, By Product

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Product, 2017–2031

        6.3.1. Metformin Hydrochloride

        6.3.2. Metformin Hydrochloride DC

        6.3.3. Others

    6.4. Market Attractiveness Analysis, by Product

7. Global Metformin Hydrochloride API Market Analysis and Forecast, by End-user

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by End-user, 2017–2031

        7.3.1. Pharmaceutical Companies

        7.3.2. Contract Research Organizations

        7.3.3. Others

    7.4. Market Attractiveness Analysis, by End-user

8. Global Metformin Hydrochloride API Market Analysis and Forecast, by Dosage Form

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Dosage Form, 2017–2031

        8.3.1. Tablet

        8.3.2. Extended Release Tablet

        8.3.3. Oral Solution

    8.4. Market Attractiveness Analysis, by Dosage Form

9. Global Metformin Hydrochloride API Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Country/Region

10. North America Metformin Hydrochloride API Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Product, 2017–2031

        10.2.1. Metformin Hydrochloride

        10.2.2. Metformin Hydrochloride DC

        10.2.3. Others

    10.3. Market Value Forecast, by End-user, 2017–2031

        10.3.1. Pharmaceutical Companies

        10.3.2. Contract Research Organizations

        10.3.3. Others

    10.4. Market Value Forecast, by Dosage Form, 2017–2031

        10.4.1. Tablet

        10.4.2. Extended Release Tablet

        10.4.3. Oral Solution

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Product

        10.6.2. By End-user

        10.6.3. By Dosage Form

        10.6.4. By Country

11. Europe Metformin Hydrochloride API Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Product, 2017–2031

        11.2.1. Metformin Hydrochloride

        11.2.2. Metformin Hydrochloride DC

        11.2.3. Others

    11.3. Market Value Forecast, by End-user, 2017–2031

        11.3.1. Pharmaceutical Companies

        11.3.2. Contract Research Organizations

        11.3.3. Others

    11.4. Market Value Forecast, by Dosage Form, 2017–2031

        11.4.1. Tablet

        11.4.2. Extended Release Tablet

        11.4.3. Oral Solution

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Product

        11.6.2. By End-user

        11.6.3. By Dosage Form

        11.6.4. By Country/Sub-region

12. Asia Pacific Metformin Hydrochloride API Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Product, 2017–2031

        12.2.1. Metformin Hydrochloride

        12.2.2. Metformin Hydrochloride DC

        12.2.3. Others

    12.3. Market Value Forecast, by End-user, 2017–2031

        12.3.1. Pharmaceutical Companies

        12.3.2. Contract Research Organizations

        12.3.3. Others

    12.4. Market Value Forecast, by Dosage Form, 2017–2031

        12.4.1. Tablet

        12.4.2. Extended Release Tablet

        12.4.3. Oral Solution

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Product

        12.6.2. By End-user

        12.6.3. By Dosage Form

        12.6.4. By Country/Sub-region

13. Latin America Metformin Hydrochloride API Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Product, 2017–2031

        13.2.1. Metformin Hydrochloride

        13.2.2. Metformin Hydrochloride DC

        13.2.3. Others

    13.3. Market Value Forecast, by End-user, 2017–2031

        13.3.1. Pharmaceutical Companies

        13.3.2. Contract Research Organizations

        13.3.3. Others

    13.4. Market Value Forecast, by Dosage Form, 2017–2031

        13.4.1. Tablet

        13.4.2. Extended Release Tablet

        13.4.3. Oral Solution

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Product

        13.6.2. By End-user

        13.6.3. By Dosage Form

        13.6.4. By Country/Sub-region

14. Middle East & Africa Metformin Hydrochloride API Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Product, 2017–2031

        14.2.1. Metformin Hydrochloride

        14.2.2. Metformin Hydrochloride DC

        14.2.3. Others

    14.3. Market Value Forecast, by End-user, 2017–2031

        14.3.1. Pharmaceutical Companies

        14.3.2. Contract Research Organizations

        14.3.3. Others

    14.4. Market Value Forecast, by Dosage Form, 2017–2031

        14.4.1. Tablet

        14.4.2. Extended Release Tablet

        14.4.3. Oral Solution

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Product

        14.6.2. By End-user

        14.6.3. By Dosage Form

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2020

    15.3. Company Profiles

        15.3.1. Auro Laboratories Limited

            15.3.1.1. Company Overview

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. Abhilasha Pharma Pvt. Ltd.

            15.3.2.1. Company Overview

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. Stanex Drugs & Chemicals Pvt. Ltd.

            15.3.3.1. Company Overview

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Fengchen Group Co., Ltd.

            15.3.4.1. Company Overview

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. NS Chemicals

            15.3.5.1. Company Overview

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Midas Pharma GmbH

            15.3.6.1. Company Overview

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Harman Finochem Ltd.

            15.3.7.1. Company Overview

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Aarti Drugs Ltd.

            15.3.8.1. Company Overview

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. Bayer AG

            15.3.9.1. Company Overview

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

        15.3.10. Ipca Laboratories Ltd.

            15.3.10.1. Company Overview

            15.3.10.2. Company Financials

            15.3.10.3. Growth Strategies

            15.3.10.4. SWOT Analysis

        15.3.11. Panacea Biotech Ltd.

            15.3.11.1. Company Overview

            15.3.11.2. Company Financials

            15.3.11.3. Growth Strategies

            15.3.11.4. SWOT Analysis

        15.3.12. Aristopharma Ltd.

            15.3.12.1. Company Overview

            15.3.12.2. Company Financials

            15.3.12.3. Growth Strategies

            15.3.12.4. SWOT Analysis

        15.3.13. Sihuan Pharmaceutical Holdings Group Ltd.

            15.3.13.1. Company Overview

            15.3.13.2. Company Financials

            15.3.13.3. Growth Strategies

            15.3.13.4. SWOT Analysis

        15.3.14. Intas Pharmaceuticals Ltd.

            15.3.14.1. Company Overview

            15.3.14.2. Company Financials

            15.3.14.3. Growth Strategies

            15.3.14.4. SWOT Analysis

        15.3.15. Bal Pharma Limited

            15.3.15.1. Company Overview

            15.3.15.2. Company Financials

            15.3.15.3. Growth Strategies

            15.3.15.4. SWOT Analysis

        15.3.16. Sohan Healthcare Pvt. Ltd.

            15.3.16.1. Company Overview

            15.3.16.2. Company Financials

            15.3.16.3. Growth Strategies

            15.3.16.4. SWOT Analysis

        15.3.17. JD Chem (I)

            15.3.17.1. Company Overview

            15.3.17.2. Company Financials

            15.3.17.3. Growth Strategies

            15.3.17.4. SWOT Analysis

        15.3.18. Kothari Phytochemicals & Industries Ltd.

            15.3.18.1. Company Overview

            15.3.18.2. Company Financials

            15.3.18.3. Growth Strategies

            15.3.18.4. SWOT Analysis

        15.3.19. Turtle Pharma Private Limited

            15.3.19.1. Company Overview

            15.3.19.2. Company Financials

            15.3.19.3. Growth Strategies

            15.3.19.4. SWOT Analysis

        15.3.20. Shijiazhuang Polee pharmaceutical Co., Ltd.

            15.3.20.1. Company Overview

            15.3.20.2. Company Financials

            15.3.20.3. Growth Strategies

            15.3.20.4. SWOT Analysis

        15.3.21. Shouguang Fukang Pharmaceutical Co., Ltd.

            15.3.21.1. Company Overview

            15.3.21.2. Company Financials

            15.3.21.3. Growth Strategies

            15.3.21.4. SWOT Analysis

        15.3.22. USV Private Limited

            15.3.22.1. Company Overview

            15.3.22.2. Company Financials

            15.3.22.3. Growth Strategies

            15.3.22.4. SWOT Analysis

        15.3.23. Exemed Pharmaceuticals

            15.3.23.1. Company Overview

            15.3.23.2. Company Financials

            15.3.23.3. Growth Strategies

            15.3.23.4. SWOT Analysis

        15.3.24. Farmhispania Group

            15.3.24.1. Company Overview

            15.3.24.2. Company Financials

            15.3.24.3. Growth Strategies

            15.3.24.4. SWOT Analysis

        15.3.25. Shandong Keyuan Pharmaceutical Co., Ltd.

            15.3.25.1. Company Overview

            15.3.25.2. Company Financials

            15.3.25.3. Growth Strategies

            15.3.25.4. SWOT Analysis

        15.3.26. Merck KGaA

            15.3.26.1. Company Overview

            15.3.26.2. Company Financials

            15.3.26.3. Growth Strategies

            15.3.26.4. SWOT Analysis

        15.3.27. Taj API

            15.3.27.1. Company Overview

            15.3.27.2. Company Financials

            15.3.27.3. Growth Strategies

            15.3.27.4. SWOT Analysis

        15.3.28. Vistin Pharma AS

            15.3.28.1. Company Overview

            15.3.28.2. Company Financials

            15.3.28.3. Growth Strategies

            15.3.28.4. SWOT Analysis

        15.3.29. Wanbury Limited

            15.3.29.1. Company Overview

            15.3.29.2. Company Financials

            15.3.29.3. Growth Strategies

            15.3.29.4. SWOT Analysis

List of Tables

Table 01: Global Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 02: Global Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 03: Global Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 04: Global Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 06: North America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 07: North America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 08: North America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 09: Europe Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 11: Europe Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: Europe Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 13: Asia Pacific Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 15: Asia Pacific Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 17: Latin America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 19: Latin America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 20: Latin America Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 21: Middle East & Africa Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Product, 2017–2031

Table 23: Middle East & Africa Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 24: Middle East & Africa Metformin Hydrochloride API Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

List of Figures

Figure 01: Global Metformin Hydrochloride API Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031

Figure 03: Global Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031

Figure 04: Global Metformin Hydrochloride API Market Value (US$ Mn), by Metformin Hydrochloride, 2017–2031

Figure 05: Global Metformin Hydrochloride API Market Value (US$ Mn), by Metformin Hydrochloride DC, 2017–2031

Figure 06: Global Metformin Hydrochloride API Market Value (US$ Mn), by Others, 2017–2031

Figure 07: Global Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031

Figure 08: Global Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031

Figure 09: Global Metformin Hydrochloride API Market Value (US$ Mn), by Pharmaceutical Companies, 2017–2031

Figure 10: Global Metformin Hydrochloride API Market Value (US$ Mn), by Contract Research Organizations, 2017–2031

Figure 11: Global Metformin Hydrochloride API Market Value (US$ Mn), by Others, 2017–2031

Figure 12: Global Metformin Hydrochloride API Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 13: Global Metformin Hydrochloride API Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 14: Global Metformin Hydrochloride API Market Value (US$ Mn), by Tablet, 2017–2031

Figure 15: Global Metformin Hydrochloride API Market Value (US$ Mn), by Extended Release Tablet, 2017–2031

Figure 16: Global Metformin Hydrochloride API Market Value (US$ Mn), by Oral Solution, 2017–2031

Figure 17: Global Metformin Hydrochloride API Market Value Share Analysis, by Region, 2020 and 2031

Figure 18: Global Metformin Hydrochloride API Market Attractiveness Analysis, by Region, 2021–2031

Figure 19: North America Metformin Hydrochloride API Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 20: North America Metformin Hydrochloride API Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 21: North America Metformin Hydrochloride API Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 22: North America Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031

Figure 23: North America Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031

Figure 24: North America Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031

Figure 25: North America Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031

Figure 26: North America Metformin Hydrochloride API Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 27: North America Metformin Hydrochloride API Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 28: Europe Metformin Hydrochloride API Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 29: Europe Metformin Hydrochloride API Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 30: Europe Metformin Hydrochloride API Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 31: Europe Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031

Figure 32: Europe Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031

Figure 33: Europe Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031

Figure 34: Europe Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031

Figure 35: Europe Metformin Hydrochloride API Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 36: Europe Metformin Hydrochloride API Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 37: Asia Pacific Metformin Hydrochloride API Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 38: Asia Pacific Metformin Hydrochloride API Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 39: Asia Pacific Metformin Hydrochloride API Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 40: Asia Pacific Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031

Figure 41: Asia Pacific Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031

Figure 42: Asia Pacific Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031

Figure 43: Asia Pacific Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031

Figure 44: Asia Pacific Metformin Hydrochloride API Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 45: Asia Pacific Metformin Hydrochloride API Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 46: Latin America Metformin Hydrochloride API Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 47: Latin America Metformin Hydrochloride API Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 48: Latin America Metformin Hydrochloride API Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 49: Latin America Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031

Figure 50: Latin America Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031

Figure 51: Latin America Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031

Figure 52: Latin America Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031

Figure 53: Latin America Metformin Hydrochloride API Market Value Share Analysis, by Dosage Form, 2020 and 2031

Figure 54: Latin America Metformin Hydrochloride API Market Attractiveness Analysis, by Dosage Form, 2021–2031

Figure 55: Middle East & Africa Metformin Hydrochloride API Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 56: Middle East & Africa Metformin Hydrochloride API Market Value Share, by Country/Sub-region, 2020 and 2031

Figure 57: Middle East & Africa Metformin Hydrochloride API Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 58: Middle East & Africa Metformin Hydrochloride API Market Value Share Analysis, by Product, 2020 and 2031

Figure 59: Middle East & Africa Metformin Hydrochloride API Market Attractiveness Analysis, by Product, 2021–2031

Figure 60: Middle East & Africa Metformin Hydrochloride API Market Value Share Analysis, by End-user, 2020 and 2031

Figure 61: Middle East & Africa Metformin Hydrochloride API Market Attractiveness Analysis, by End-user, 2021–2031

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved